Theravance Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St

February 28, 2025

Theravance Biopharma (NASDAQ:TBPH) Full Year 2024 Results

Key Financial Results

Revenue: US$64.4m (up 12% from FY 2023).
Net loss: US$56.4m (loss widened by 2.2% from FY 2023).
US$1.16 loss per share (further deteriorated from US$1.00 loss in FY 2023).

earnings-and-revenue-growth — NasdaqGM:TBPH Earnings and Revenue Growth February 28th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Theravance Biopharma Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) missed analyst estimates by 9.8%.

Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are down 4.0% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of Theravance Biopharma's balance sheet and an in-depth analysis of the company's financial position.

If you're looking to trade Theravance Biopharma, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if Theravance Biopharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.